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Abstract
Background—Little is known about fertility choices and pregnancy outcome rates among HIV-
infected women in the current combination ART era.
Objective—To describe trends and factors associated with live-birth and abortion rates among 
HIV-positive and high-risk HIV-negative women enrolled in the Women’s Interagency HIV Study 
(WIHS) in the United States.
Study Design—We analyzed longitudinal data collected from October 1st 1994 to September 
30th 2012 through WIHS. Age-adjusted rates per 100 person-years (PY) live-births, and induced 
abortions were calculated by HIV serostatus over four time periods. Poisson mixed effects models 
containing variables associated with live-births and abortions in bivariable analyses (p<0.05) 
generated adjusted incidence rate ratios (aIRRs) and 95% confidence intervals.
Results—There were 1,356 pregnancies among 2,414 women. Among HIV-positive women, age-
adjusted rates of live-birth increased from 1994-1997 to 2006-2012 (2.85/100PY to 7.27/100PY, p-
trend<0.0001). Age-adjusted rates of abortion in HIV-positive women remained stable over these 
time periods (4.03/100PY to 4.29/100PY, p-trend=0.09). Significantly lower live-birth rates 
occurred among HIV-positive compared to HIV-negative women in 1994-1997 and 1997-2001, 
however rates were similar during 2002-2005 and 2006-2012. Higher CD4+ T cells/mm3 (≥350 
aIRR=1.39 [1.03-1.89] versus <350) was significantly associated with increased live-birth rates, 
while combination antiretroviral treatment (cART) use (aIRR=1.35 [0.99-1.83]) was marginally 
associated with increased live-birth rates. Younger age, having a prior abortion, condom use and 
increased parity were associated with increased abortion rates among both HIV-positive and HIV-
negative women. CD4+ T-cell count, cART use, and viral load were not associated with abortion 
rates.
Conclusions—Unlike earlier periods (pre-2001) when live-birth rates were lower among HIV-
positive women, rates are now similar to HIV-negative women, potentially due to improved health 
status and cART. Abortion rates remain unchanged illuminating a need to improve contraceptive 
services.
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Introduction
Pregnancy and family planning among women living with HIV involves complex decision-
making and clinical management 1, 2. Considerable improvements in the treatment and care 
of HIV-positive women has led to increased life expectancy and improved health 3, 4. 
Additionally, improved clinical management of pregnant women has led to near elimination 
of perinatal HIV transmission among those on effective combination antiretroviral treatment 
(cART) throughout pregnancy 5-7. The potential of cART to reduce maternal-to-child 
transmission of HIV has affected the reproductive decisions of women living with HIV, with 
more women now choosing to have children 8-11. However, family planning is often 
incompletely addressed within the current HIV care paradigm. Many pregnancies occurring 
among HIV-positive women, similar to the general population, are unplanned. Though data 
are scant, it has been estimated that up to 80% of pregnancies occurring among HIV-positive 
women in the United States (US) are unintended 12-14, compared to approximately 50% in 
the general population. This highlights the importance of understanding reproductive health 
needs of this cohort and providing targeted family planning options as part of routine HIV 
care.
It is still unclear how pregnancy rates and outcomes have changed over the past 20 years 
among HIV-positive women, spanning the introduction of cART, compared to HIV-negative 
women. A 1994-2002 Women's Interagency HIV Study (WIHS, an ongoing multicenter 
prospective cohort study of HIV infection and outcomes among women with and without 
HIV) analysis found pregnancy rates of 7.4 and 15.2/100 person-years among HIV-positive 
and high-risk negative women, respectively 11. In a more recent 2002-2009 WIHS study, 
Linas et al reported that HIV infection was associated with a 40% reduction in pregnancy 
incidence among HIV-positive versus HIV-negative women adjusting for age, number of 
sexual partners, contraception, parity and alcohol use 15.
This study aims to describe trends in pregnancy and pregnancy outcomes, including live-
birth and abortion, over the past 20 years in HIV-positive and negative women enrolled in 
the WIHS cohort. We further determine factors associatedwith live-births and abortion, 
specifically focusing on the role of HIV viral load and cART, to better understand the impact 
of improved immune function and other factors in pregnancy outcomes.
Materials and Methods
We performed a longitudinal analysis of WIHS data collected between October 1st 1994 to 
September 30th 2012 16. HIV-positive and high-risk negative women were recruited from 
similar sites with more than half of the participants living below the federally defined level 
of poverty and frequency matched based on demographics and key risk factors for acquiring 
HIV, such as drug use and number of partners, with recruitment targets adjusted when 
imbalances arose16, 17. Enrollment for WIHS began in 1994 with 6 sites (Bronx, Brooklyn, 
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Chicago, Washington D.C., Los Angeles, San Francisco), and has continued with 6 month 
visits using trained interviewers, where visits include detailed questionnaires including ART 
use, medical history, and medication use, a clinical examination and comprehensive 
laboratory testing (including CD4 T-cell count and HIV viral load). WIHS had 
replenishment enrollment in 2001-2002, 2011-2012 and 2013-2015, now with a total of 9 
US sites. Data from the 6 original sites are included in this study. IRB approval was obtained 
from each WIHS site prior to study enrollment. Data for this evaluation utilized de-identified 
data.
As obstetrical care was received outside of the study, pregnancy outcomes and associated 
dates were reported by the participant. Outcomes were classified as: induced abortion for 
those who terminated the pregnancy, live-birth for a baby born alive, and non-viable for 
spontaneous abortion, ectopic pregnancy or still-birth.
Women were included in this analysis if they attended at least two WIHS visits. Women not 
at risk for pregnancy due to history of hysterectomy, tubal ligation or bilateral oophorectomy 
and women over the age of 45 were excluded/censored from analysis.
Rates for induced abortion, live-birth, non-viable pregnancy and all pregnancy outcomes 
combined were the number of pregnancies divided by the person-years at-risk over the entire 
study, stratified by time: 1994-1997, 1998-2001, 2002-2005, 2006-2012. Pregnancy rates per 
100 person-years were directly adjusted using the population age distribution of women with 
pregnancy outcomes in 1996, similar to the methods used in the prior publication by Massad 
in 200411. Due to the zero birth rate among older age groups, 95% confidence intervals (CI) 
for directly age adjusted rates are based on a modified gamma distribution 18. The Mantel-
Haenszel chi-square quantified whether age adjusted pregnancy rates differed by HIV 
serostatus within each time period 19. Trend tests evaluated trends in adjusted rates by time 
interval by serostatus.
Bivariable associations between covariates (both baseline variables and time-varying) and 
live-birth and abortion were determined using a Poisson regression model with an offset for 
years in each risk group. Baseline covariates of interest were recorded at the participant’s 
first WIHS visit and included race/ethnicity, income, marital status, education, employment 
status, insurance status, WIHS site, number of male sexual partners, parity, history of 
abortion, prior sexually transmitted infection, and year of first cART, where cART was 
defined as 3 or more antiretroviral drugs used concurrently by self-report . Time-varying 
covariates reflect activity for the time since the last WIHS visit and included contraception 
use, characterized as hormonal or long-acting reversible contraceptive (LARC) including 
intrauterine contraception and implants compared to none or other method use (condoms, 
withdrawal, diaphragm). Condom use was dichotomized into any condom use since the last 
visit versus no use. Alcohol use was dichotomized into self-report of 0 to 7 drinks compared 
to more than 7 drinks per week. Current cigarette smoking and illicit drug use (marijuana/
hash, crack/cocaine, methamphetamine or intravenous drug use) were positive if the 
individual reported any use since the last visit. A time-varying composite for chronic 
medical conditions (stroke, myocardial infarction, diabetes, hypertension, deep vein 
thrombosis, pulmonary embolus (PE), cancer or tuberculosis (TB)) was created. HIV-
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specific factors were incorporated for the HIV-positive cohort and included use of cART at 
the visit, viral load (categorized as <4 and ≥4 log10 copies or 10,000), and CD4+ T-cell 
count (<350 and ≥350 cells/mm3). Categorization for viral load and CD4+ T-cell count was 
determined a priori based upon clinical significance and the approximate median value for 
the WIHS cohort in 2004 based on prior publications11.
Poisson mixed effects models with a random intercept and offset for years since last visit 
were created to evaluate multivariate associations with live-birth or abortion including all 
variables with significance by bivariable association (p<0.05), crude unadjusted incidence 
rate ratios (cIRR), and adjusted incidence rate ratios (aIRR) with 95% confidence intervals 
were obtained.
Results
Among 4346 (1089 HIV-negative, 3232 HIV-positive, 25 seroconverters) women enrolled in 
WIHS during the study period, about 56% (n=2414) were included in this analysis. Of the 
1952 women excluded, 36% (n=707) were older than 45 years, 61% % not at risk for 
pregnancy (n=568 hysterectomy, n=608 tubal ligation, n=7 bilateral oophoretomy), and 3% 
were excluded for other reasons (n=13 HIV sereoconverters, n=25 did not have 2 eligible 
visits to analyze, n=4 pregnancy outcome data was incomplete). This analysis included 
1,750 HIV-positive and 664 HIV-negative women with a total of 1,356 pregnancies reported 
over 16,670 person-years (8.13/100 PY, unadjusted). Of these pregnancies, 586 (43.2%) 
ended in live-birth, 469 (34.6%) in abortion, and 301 (22.2%) in a non-viable pregnancy. 
Supplemental tables 1a and 1b show that about 50% were African American, single, had at 
least a high school education, and were employed and insured. Over one-half of the women 
had a prior abortion and over one-half had at least 1 live-birth. HIV-positive women were 
older than HIV-negative women. Contraception use, other than condoms, among among all 
women was low at approximately 15% of included visits. HIV-positive women were on 
cART during about half of study visits, and for over 60% of all visits viral loads were 
satisfactorily suppressed (<4 log10 copies/ml) and CD4+ T-cell counts adequate (≥350 cell/ 
mm3).
Pregnancy outcome rates over time by HIV serostatus
For all-pregnancy outcomes combined, age-adjusted rates (Supplemental Table 2, Figure 
1A) among HIV-positive women demonstrated a non-significant increasing trend over time 
(p-trend=0.088). While the overall age-adjusted rates were lower among HIV-positive 
women compared to HIV-negative women, significantly lower rates occurred during 
1994-1997 and 1998-2001 for HIV-positive women compared to HIV-negative, whereas 
rates during 2002-2005 and 2006-2012 were similar to HIV-negative women.
Similar results were seen in age-adjusted live-birth rates. There was a significant increase 
observed over time (Figure 1B, HIV-positive p-trend<0.0001) for HIV-positive women, with 
no significant change observed among HIV-negative women (p-trend=0.76). The overall 
age-adjusted live-birth rate was lower for HIV-positive compared to HIV-negative women, 
with significantly lower rates at earlier time periods (1994-1997, 1998-2001) and no 
significant difference at the later time periods (2002-2005, 2006-2012).
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Age-adjusted abortion rates remained relatively stable over time (Figure 1C, HIV-positive p-
trend=0.093) with age-adjusted rates remaining between 3.4 and 4.4/100 person-years. 
While age-adjusted abortion rates among HIV-negative women decreased over time (p-
trend=0.0015), the rates for HIV-positive women were significantly lower during the earlier 
time periods (1994-1997, 1998-2001) with no difference at periods (2002-2005, 2006-2012). 
Of the 301 pregnancies (181 HIV positive and 120 HIV negative) that ended in non-viable 
pregnancies, there was no difference in the overall age-adjusted non-viable pregnancy rate 
between HIV negative and HIV positive (p=0.611) and no significant trend over the years of 
observation (p-trend = 0.534 and 0.149 for HIV positive and HIV negative, respectively).
Associations with live birth rates
Bivariable associations are presented in Supplemental Table 3. Notably, among HIV-negative 
and HIV-positive women, income, insurance status, and contraception use were not 
associated with live-birth rates. For HIV-positive women, cART use (cIRR=1.69, 95%CI 
1.32-2.16), lower viral loads (<4 log10 copies/ml cIRR=2.90, 95%CI 2.17-3.87 versus ≥4 
log10 copies/ml) and higher CD4+ T-cell counts (≥350 cells/mm3 cIRR=2.70, 95%CI 
2.00-3.57 versus <350 cells/mm3) were associated with increased live-birth rates in crude 
analyses.
In multivariable models among HIV-negative women (Table 1), those living with a partner 
(versus married, aIRR=1.65, 95%CI 1.07-2.54), and with less than a high-school education 
(aIRR=1.38, 95%CI 1.02-1.85) had higher live-birth rates, while older age (≥35 aIRR=0.22, 
95%CI 0.14-0.35 versus <25), history of abortion (aIRR=0.73, 95%CI 0.55-0.98), using 
condoms (aIRR=0.55, 95%CI 0.41-0.73), marijuana (aIRR=0.57, 95%CI 0.39-0.84) or drug 
use (aIRR=0.32, 95%CI 0.15-0.66) were associated with decreased live-birth rates. For HIV-
positive women (Table 1), older age (≥35 aIRR=0.14, 95%CI 0.08-0.23 versus <25), alcohol 
consumption (drinking more than 7 versus <7 drinks per week, aIRR=0.47, 95%CI 
0.22-0.97), using condoms (aIRR=0.73, 95%CI.56-0.97), and CD4+ T-cell count <350 
cells/mm3 (aIRR=0.72, 95%CI 0.53-0.97, versus ≥350 cells/mm3) were associated with 
lower live-birth rates. There was a non-significant trend towards increased live-birth rates 
among those using cART compared to non-users (aIRR=1.35, 95%CI 0.99-1.83) in the 
multivariable model that included variables such as CD4+ T-cell count and viral load. In 
multivariate models for both HIV-positive and HIV-negative women, time period was not 
significantly associated with live-birth.
Associations with abortion rate
Bivariable associations with abortion rate are presented in Supplemental Tables 3a and 3b. 
Notably, among HIV-negative and HIV-positive women, income, marital status, insurance 
status, contraception use, and number of male sex partners were not associated with abortion 
rates. For HIV-positive women, cART use was significantly associated with reduced 
abortion rates (cIRR=0.61, 95%CI 0.44-0.85) while lower viral loads (<4 log10 copies/ml 
cIRR=1.43, 95%CI 1.03-1.98 versus ≥4 log10 copies/ml) and higher CD4+ T-cell counts 
(≥350 vs <350 cells/mm3 cIRR=1.82, 95%CI 1.32-2.50) were each significantly associated 
with increased abortion rates.
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Multivariable models for abortion rates for HIV-negative and HIV-positive women are 
presented in Tables 2. Among HIV-negative women, older age was associated with 
decreased abortion rates (≥35 versus <25, aIRR=0.07, 95%CI 0.04-0.13), while increased 
parity (≥3 versus 0, aIRR=3.14, 95%CI 1.66-5.93), having a history of abortion (aIRR=1.56, 
95%CI 1.06-2.30), and use of condoms (aIRR=2.18, 95%CI 1.58-3.01) were associated with 
increased rates of abortion. Further, study site was also associated with abortion rate, with 
significantly fewer abortions among participants at the Washington, D.C. and Chicago sites 
compared to the Bronx site (aIRR=0.47, 95%CI 0.22-0.99 and aIRR=0.18, 95%CI 
0.06-0.52, respectively).
For HIV-positive women, abortion rates were negatively associated with age (≥35 versus 
<25, aIRR=0.14, 95%CI 0.07-0.25) and positively associated with prior abortion 
(aIRR=1.72, 95%CI 1.16-2.55), study site (Brooklyn versus Bronx, aIRR=1.96, 95%CI 
1.07, 3.59), and condom use (aIRR=2.40, 95%CI 1.52-3.79). Prior self-reported sexually 
transmitted infection was associated with decreased abortion rates (aIRR=0.63, 95%CI 
0.43-0.92). Time-period, cART use, CD4+ T-cell count and viral load were not associated 
with abortion rates in the multivariate model.
Discussion
Although reduced pregnancy and live-birth rates have been the reported among HIV-positive 
versus HIV-negative women 11, 20 during the earlier HIV epidemic, we demonstrate that in 
the current cART era these rates have increased among HIV-positive women and are now 
comparable to rates among HIV-negative women. Studies in sub-Saharan Africa have 
suggested a similar trend towards increasing pregnancy rates with ART use 21, however this 
trend among women in developed countries has not been previously demonstrated. Increased 
contraception, sterilization and sexual abstinence may have led to initial drops in pregnancy 
rates among those living with HIV 22, perhaps driven by fear of transmission, poor overall 
health status, and stigma. Increases in pregnancy and live-birth rates may be reflective of 
improved fecundability, improved health, and changing fertility intentions. Fertility intention 
may be influenced by overall improvement in perceived wellbeing, life expectancy, reduced 
fear of perinatal HIV transmission, and more positive attitudes about pregnancy among HIV 
care providers and communities. Women with lower CD4+ T-cell counts, higher viral loads 
and not using cART continued to have lower live-birth rates. Further, while age-adjusted 
live-birth rates were significantly increased, when factors such as cART use, viral load and 
CD4+ T-cell count were included in our models, time period was no longer associated with 
live-birth rate. This suggests that HIV-related clinical factors play a central role in the 
increased trend. Interestingly, although cART use, CD4 count, and viral load were 
significant in the bivariate analysis, after including them in the multivariable model and also 
adjusting for other important covariates, only CD4 +T-cell count was significantly associated 
with increased live births rates.
Approximately half of all pregnancies in the US are unintended; among those, 40% will end 
in induced abortion 23. Estimates for unintended pregnancy among women living with HIV 
may be much higher 24. A 2014 study among HIV-positive pregnant women found 23% had 
an unplanned pregnancy, 58% were ambivalent, and only 19% reported a planned 
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pregnancy 14. Previous analysis from the WIHS cohort had documented reduced abortion 
rates during the early HIV epidemic 11 in conjunction with fewer overall pregnancies. While 
our data and others have shown a decrease in abortion rates over the last decade among HIV-
negative women 25, we demonstrate that the rate among those living with HIV has not 
altered. Notably, cART use, CD4+ T-cell count, and viral load were not associated with 
abortion rates among HIV-positive women, suggesting that for many women the complex 
decision-making regarding pregnancy continuation and abortion may not be strongly 
influenced by their HIV disease state. Similar to previous literature, predictors of abortion 
among both HIV-positive and HIV-negative high-risk women include younger age, increased 
parity and history of having had an abortion 23, 25, 26. These high-risk groups should be 
targeted for contraceptive counseling.
Condoms were the dominant form of contraception in our cohort. Given high, typical-use 
pregnancy rates of 18%/year with condom use 27, condoms alone have limited utility for 
unintended pregnancy prevention. Use of other contraceptives among our cohort was low, 
with women reporting either a hormonal or a LARC method at only 15% of visits. 
Ineffective contraception use with a high reliance on condoms alone among WIHS 
participants has previously been reported, where HIV positive women in this cohort have not 
experienced an increase in LARC use seen in HIV-negative women28. As contraceptive use 
was not associated with live-birth rates, we can conclude that many women may be offered 
or choose less effective methods, do not use them consistently or correctly, and continue 
with pregnancy when contraceptives fail. Previous studies have demonstrated poor 
utilization of the most effective long-term contraceptives among women living with HIV 28, 
despite increasing uptake nationally 29. Long-acting contraceptive options, such as 
intrauterine devices (IUDs) and contraceptive implants, are safe for HIV-positive and at-risk 
women, have high continuation rates, and reduce unintended pregnancy rates 30, 31. With 
potentially increased health engagement among women in HIV care, opportunities for 
integrated family planning services must be sought to reduce barriers to safe contraception. 
Educational messaging must shift from condom use alone to encourage dual protection, with 
a hormonal or LARC method for pregnancy prevention and concurrent use of condoms for 
effective sexually transmitted infection (STI) and HIV prevention. Novel approaches may be 
needed to successfully integrate reproductive health services into HIV care.
This study has several limitations. Information on pregnancy outcomes and covariates were 
based on self-report and are thus prone to potential misclassification; however self-reported 
data used in other WIHS studies has been strongly correlated with clinical outcomes and 
several personal self-reported questions gathered throughout the WIHS cohort may not be 
routinely available in clinical chart reviews or provider generated database evaluations. 
Study intervals of six months for assessment of time-varying covariates limited our ability to 
evaluate changes during those intervals; however this is likely to be more generalizable to 
data that could be collected in a clinical setting. Moreover, we do not have reliable data on 
pregnancy intention or abortion access. Eligibility criteria in this longitudinal cohort 
potentially limits external validity. The average age of our cohort is relatively advanced, thus 
results may not reflect the younger HIV-positive or high-risk HIV-negative women or those 
with perinatally-acquired HIV. Lastly, we dichotomized CD4 T-cell count and viral load 
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based on predetermined values to reflect poor HIV control, however other lower cut-offs are 
often used for defining virologic suppression.
In conclusion, we demonstrate that overall pregnancy rates are now similar between HIV-
positive and high-risk HIV-negative women, possibly due to improved health status among 
HIV-positive women coupled with shifting attitudes due to reduced risk of maternal-to-child 
transmission. With that said, abortion rates have remained consistent and do not appear to be 
associated with HIV related health variables, indicating that unintended pregnancy among 
all individuals need to be addressed. Given high failure rates with condom use alone, dual 
protection with hormonal contraceptives or nonhormonal IUDs should be strongly 
encouraged for women seeking contraception. Integrating reproductive health services into 
HIV clinical care can reduce barriers and improve care for high-risk women and provide an 
important opportunity to address family planning and safe conception practices.
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Condensation
Live-birth rates among HIV-positive women have increased over 2 decades, are now 
similar to HIV-negative women and associated with ART use.
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Figure 1. 
Age-adjusted rate estimates of all pregnancies (Figure 1A), live-birth (Figure 1B) and 
abortion (Figure 1C) from 1994 to 2012 among high-risk HIV-negative (red) and HIV-
positive (blue) women enrolled in the Women’s Interagency HIV study (WIHS)
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Table 2
Significant predictors from multivariable model of abortion rate among HIV-negative and HIV-positive women 
in the WIHS
HIV-negative HIV-positive
Variable aIRR* 95%CI aIRR* 95%CI
Age 25-29 vs <25 0.49 0.33 0.74 0.44 0.26 0.76
Age 30-34 vs <25 0.27 0.17 0.43 0.29 0.16 0.51
Age >=35 vs <25 0.07 0.04 0.13 0.14 0.07 0.25
Brooklyn vs Bronx ------ ------ ------ 1.96 1.07 3.59
DC vs Bronx 0.47 0.22 0.99 ------ ------ ------
Chicago vs Bronx 0.18 0.06 0.52 ------ ------ ------
Baseline Parity 1-2 vs 0 2.55 1.54 4.23 1.73 0.99 3.03
Baseline Parity >=3 vs 0 3.14 1.66 5.93 2.64 1.41 4.93
Prior Abortion vs No 1.56 1.06 2.30 1.72 1.16 2.55
Prior STI vs No ------ ------ ------- 0.63 0.43 0.92
Use Condom vs No 2.18 1.58 3.01 2.40 1.52 3.79
HS = high school; vs=versus, CI=confidence interval, STI= sexually transmitted infection vs=versus, CI=confidence interval
*
aIRR, adjusted incidence rate ratio;
Poisson mixed model with random intercept for each subject included all variables with significant bivariable models for HIV-positive or negative 
(p<0.05); Other variables controlled for in model: race, year, site, education, employment status, alcohol use, any health related issue, drug use, 
prior STI, and for HIV-positive women: cART use, CD4+ T-cell count, first year on cART, viral load.
Variable considered but not included in model as significant in bivariable analysis: income, marital status, insurance status, number of male sex 
partners, prior non-viable pregnancy, contraception use), current cigarette smoking, current marijuana use.
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